08 Mar, 2023

Pharmacological characteristics of brexpiprazole (REXULTI®), a serotonin-dopamine activity modulator　

Dr Tetsuro Kikuchi discusses the development of brexpiprazole (REXULTI), a serotonin-dopamine activity modulator used in the treatment of schizophrenia. Dr Kikuchi's insights allow for a deeper understanding of the drug design process, the antipsychotic mode of action of brexpiprazole and its potential position in the treatment of schizophrenia.1

References

  1. REXULTI® Australian Approved Product Information.

Internal ID: AU-REXU-0368. Mar 2023. Video AU-REXU-0367. Mar 2023

  • Box
    Body

    REXULTI PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia

  • text
    Body

    Please review Approved Product Information before prescribing.
    Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:

    REXULTI PI

    REXULTI® is a registered trademark of H. Lundbeck A/S. REXULTI® is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.

Related

BROUGHT TO YOU BY

Lundbeck
© 2022 Lundbeck Australia

LUNDBECK AUSTRALIA PRODUCTS

Privacy and disclaimer

Cookies

Contact Us

Lundbeck Australia Pty Ltd 
1 Innovation road, Ground floor
NSW 2113, North Ryde, Australia
Phone +61 2 8669 1000
Fax +61 2 8669 1090

 

otsuka logo

 

Otsuka Australia Pharmaceutical Pty. Ltd

subscribe newsletter

Sign up for newsletter

This website is intended for viewing only by health care professionals in Australia.

All information provided within this site is intended only for residents of Australia.